



FRONTAGE Offers Full-Service Radiolabeled hAME Studies to Support Your Drug Development Programs:

- Expert staff with an average of 25 years' experience in QWBA, dosimetry, hAME studies, metabolite profiling/characterization, and early phase clinical research
- Purpose-built 160-bed clinical facility in northern NJ with a dedicated unit for hAME studies
- On-site compounding pharmacy for dose preparation
- Seamless integration between Frontage Clinical and DMPK teams for sample analysis and real-time radioactivity counting allowing for timely subject release
- Metabolite identification, characterization and profiling of samples by industry's leading experts equipped with the state-of-the-art instrumentation
- QWBA and radiation dosimetry reports provided to clients prior to the conduct of hAME studies
- Relative exposure of major metabolites evaluated to confirm adequate coverage in preclinical toxicology species
- A comprehensive hAME report

